Notable Downgrades: Alexion Pharma (ALXN), Marvell Technology (MRVL), Solera Holdings (SLH), Seattle Genetics (SGEN), XPO Logistics (XPO)

Analysts at Barclays downgraded Alexion Pharmaceuticals, Inc. (ALXN) from ‘Overweight’ to ‘Equal Weight’ in a research report issued to clients on Monday. The target price for ALXN is lowered from $220 to $205. On valuation measures, Alexion Pharmaceuticals Inc. stock it’s trading at a forward P/E multiple of 27.59x, and at a multiple of 56.78x […] View the full post at: Notable Downgrades: Alexion Pharma (ALXN), Marvell Technology (MRVL), Solera Holdings (SLH), Seattle Genetics (SGEN), XPO Logistics (XPO) Related posts: Marvell Technology (MRVL) Has Turned the Corner Cognizant Technology On a Tear and Still Undervalued A New (Unfortunate) Record: Advanced Technology Trade Deficit